A number of novel MSAs that do not bind covalently are able to overcome the acquired resistance of cancer cells, either because they are not substrates for the P-gp drug efflux pump or because they bind with relatively equal affinity to all the main β-tubulin isotypes, including β-III tubulin that is known to confer resistance in some cell lines [41]. This evidence concerns the gene PGP and cancer.